Market capitalization | $148.25m |
Enterprise Value | $58.57m |
P/E (TTM) P/E ratio | negative |
P/B ratio (TTM) P/B ratio | 1.52 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-81.36m |
Cash position | $112.68m |
EPS (TTM) EPS | $-1.36 |
P/E forward | negative |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
7 Analysts have issued a Black Diamond Therapeutics Inc forecast:
7 Analysts have issued a Black Diamond Therapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.34 -0.34 |
90%
90%
|
|
EBITDA | -81 -81 |
4%
4%
|
EBIT (Operating Income) EBIT | -81 -81 |
7%
7%
|
Net Profit | -73 -73 |
13%
13%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Black Diamond Therapeutics, Inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Head office | United States |
CEO | Mark Velleca |
Employees | 54 |
Founded | 2014 |
Website | www.blackdiamondtherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.